David Einhorn acquired 2.24 Million Talis Biomedical shares worth $1.4 Million. That's 0.11% of their equity portfolio (31st largest holding). The investor owns 8.74% of the outstanding Talis Biomedical stock. The investor's estimated purchase price is $9.36 Million, resulting in a loss of 85%.